Mesencell Biotech GmbH/Ltd is a biotech company founded by Dr Steven James Kellner and focuses on installing and maintaining biotech laboratories worldwide producing cell and tissue products, such as but not limited to adipose derived mesenchymal stem cells, research and development,  preclinical and clinical studies in all areas of translational and cellular medicine. Read more.


Latest Post

Fields of application

Anti Ageing/Anti Morbidity

With continuously increasing life expectancy, the impact of chronic diseases and dependencies, for which no specific cures are available, also increases. This leads to an enormous burden to individuals and societies alike, which threatens to overwhelm conventional curative and care models in medicine. Unfortunately healthy life expectancy, the number of years spent free of disabilities, has grown slower than life expectancy in a number of countries. Within the European Union, for instance, life expectancy at age 50 has grown …Read more.

Alzheimer Disease

Alzheimer’s disease (AD) is the leading cause of age related dementia, afflicting one in every eight people over the age of 65. Unfortunately, the incidence of dementia is expected to quadruple over the next 40 years, such that more than 115 million people will be afflicted world-wide by 2050. Currently approved therapies offer only marginal, temporary relief and fail to modify the underlying disease pathology. Thus, there is a critical and urgent need to examine novel and combinatorial approaches to treat this devastating disorder. Read more

Cardiovascular Disease

Myocardial infarction (MI) causes the loss of cardiac tissue and scar formation, which ultimately lead to heart failure. According to the World Health Organization, heart failure initiated by MI and coronary artery disease accounts for 29% of deaths worldwide. However, human heart tissue does not regenerate spontaneously, thus „regenerative medicine“ represents a promising alternative treatment for MI. Cardiac tissue regenerative medicine involves … Read more.


Diabetes mellitus (diabetes) is a devastating disease that affects millions of people globally and causes a myriad of complications that lead to both patient morbidity and mortality. Currently available therapies, including insulin injection and beta cell replacement through either pancreas or pancreatic islet transplantation, are limited by the availability of organs.

Read more.


Among the various forms of degenerative joint disease, osteoarthritis (OA) is by far the most common and represents a painful chronic condition that can affect any synovial joint. Disease prevalence is increasing in parallel with an aging population and will impose significant socioeconomic burden over the coming decades. Arthritis is the most common source of disability among adults in the United States;


Read more.


Stroke is the most common cause of adult-acquired disability in the developed and developing world. With an aging population, the incidence and prevalence of stroke are predicted to rise. Stroke is an acute-onset clinical syndrome that develops following a vascular insult to the brain. Brain ischemia resulting from thromboembolism or less frequently, in situ thrombosis, constitutes 80%−85%, and haemorrhage resulting from hypertension or vessel wall pathology constitutes 15%−20% of all strokes. … Read more.

Parkinson Disease

Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the classical motor symptoms of bradykinesia, rigidity and tremor. The pathological hallmark of PD is a gradual loss of nigrostriatal dopamine (DA) neurons, but neuronal degeneration also occurs in non-DA-ergic systems. Treatments aiming to relieve PD motor symptoms include the use of oral preparations of L-3,4-dihydroxyphenylalanine (L-DOPA) and DA receptor agonists and, in more advanced cases, the use of apomorphine, delivery of L-DOPA through continuous intestinal administration, and deep brain stimulation in sub thalamic nucleus and globus pallidus via surgically implanted electrodes. These treatments have proved effective to a point, but they can generate adverse effects, such as LDOPA-induced dyskinesias, and they do not counteract the progression of the disease.


Read more.

Skin Disease

Coming soon.



Read more.